Why the study?
Treatment decisions for aggressive non-Hodgkin lymphoma in elderly and frail patients remain challenging due to clinical heterogeneity, comorbidities, and frailty.
Comprehensive geriatric assessment is necessary for risk stratification in elderly and frail patients with aggressive non-Hodgkin lymphoma to guide appropriate treatment decisions.
Answers are grounded in this paper and cite their sources.
May support CGA-guided decisions in elderly NHL; leaves open prospective validation before practice change.
Treatment decisions for aggressive non-Hodgkin lymphoma in elderly and frail patients still remain challenging. The heterogeneity of elderly patients consists of various physical and psychological states, coexisting comorbidities as well as frailty and socioeconomic status. Comprehensive geriatric assessment in elderly patients is efficient and necessary for risk stratification to identify fit patients without cardiac comorbidities who can tolerate curative treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) and those who are not suitable for a standard regimen. If anthracycline-containing therapy is not feasible, alternative treatment options have to be carefully evaluated and individual risk factors have to be considered.
No takes yet. Share an insight, caveat, or question.
Schmittlutz et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: